Elvitegravir (Viteka)

Published October 15, 2012; Updated September 2014
Susa Coffey, MD
http://hivinsite.ucsf.edu/InSite?page=ar-07-02
Selected Reference
6. Molina JM, LaMarca A, Andrade-Villanueva J, et al; Study 145 Team. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. Lancet Infect Dis. 2012 Jan;12(1):27-35.